Table 1.
Baseline characteristics
| Variable | N = 82a |
|---|---|
| Age, median (range), years | 69 (36.2–86.5) |
| Sex, n (%) | |
| Male | 57 (70) |
| Race, n (%) | |
| Non-white | 4 (5) |
| White | 45 (55) |
| Not specified | 33 (40) |
| White blood cell count, median (range), cells/L | 11.8 ×109 (0.1–207.5 ×109) |
| Hemoglobin level, median (range), g/dL | 10.3 (3.7–15.5) |
| Platelet count, median (range), cells/L | 89 ×109 (1.8–13.86 ×109) |
| Albumin level (n = 80), median (range), g/dL | 4.3 (2.3–5.1) |
| Lactate dehydrogenase level (n = 80), median (range), U/L | 571 (228–2897) |
| Ferritin level (n = 58), median (range), ng/mL | 289 (31–3868) |
| B2-microglobulin level (n = 43), median (range), µg/mL | 3.7 (1.2–33) |
| Absolute neutrophil count, median (range), cells/µL | 59 (0–43.8) |
| Basophils, median (range), % | 0 (0–24.3) |
| Eosinophils (n = 81), median (range), % | 1 (0–25) |
| Hepatomegaly, n (%) | |
| Yes | 4 (5) |
| No | 78 (95) |
| Splenomegaly, n (%) | |
| Yes | 15 (18) |
| No | 66 (80) |
| History of splenectomy | 1 (1) |
| Transfusion dependency, n (%) | |
| Yes | 32 (39) |
| No | 46 (56) |
| Unknown | 4 (5) |
| Treatment, n (%) | |
| HMA | 19 (23) |
| HMA+ combination | 13 (16) |
| TKI | 1 (1) |
| Chemotherapy | 12 (15) |
| Supportive therapy | 37 (45) |
| Bone marrow monocytes, median (range), % | 12 (0–53) |
| Bone marrow fibrosis grade, n (%) | |
| 0 | 3 (4) |
| 1 | 63 (77) |
| 2 | 16 (20) |
| IPSS cytogenetic risk group | |
| Poor | 7(8.5%) |
| Intermediate | 15(18.3%) |
| Good | 57(69.5%) |
| Very Good | 3(3.7%) |
| Ringed sideroblasts (n = 58), median (range), % | 0(0–92) |
| Bone marrow blast %, median (range), n=81 | 5% (0–20%) |
| Peripheral blood blast %, median (range) | 0%(0–14%) |
| Time from diagnosis to treatment (n = 45), median, (range), months | 1.9 (0–59.7) |
a
Unless otherwise noted.
Abbreviations: HMA=Hypomethylating agent, TKI=Tyrosine kinase inhibitor.